Clinical trials: Cardiometabolic Disease
Type 2 Diabetes
Impact of a Digital Self-Management Program on A1C for Individuals With Type 2 Diabetes
The goal of this study is to evaluate a digital chronic disease self-management program designed to provide virtual support and guidance for patients with type 2 diabetes.
- Trial name
- NCT04892680
- Testing
- Online Diabetes Self-Management Education and Support (DSMES) Program
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Omada Health, Inc.
Cardiometabolic Syndrome
Establishing Clinical Utility Evidence for Chronic Disease Management Testing Patient Study
This is a national-level research study of primary care physicians. The purpose of this study is to assess the clinical evaluation and management (drug, procedures, counseling, and others) of a subset of common patient care…
- Trial name
- NCT05910684
- Testing
- Aegis CDM Test and Educational Materials
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Qure Healthcare, LLC
Coronary Artery Disease
Cardiometabolic Risk in Cardiac Rehab
1. Primary Objectives: To characterize cardiometabolic risk factor profiles of patients entering cardiac rehab using traditional approaches (eg LDL-C) as well as a more comprehensive panel of cardiovascular and metabolic…
- Trial name
- NCT01985048
- Where
- 3 sites in United States
- Volunteers
- 500 people
- Sponsor
- Health Diagnostic Laboratory, Inc.
Cardiometabolic Syndrome
Establishing Clinical Utility Evidence for Chronic Disease Management Testing
This is a national-level research study of primary care physicians. The purpose of this study is to assess the clinical evaluation and management (drug, procedures, counseling and other) of a subset of common patient care…
- Trial name
- NCT05192590
- Testing
- Educational Materials and Chronic Disease Management Test (CDMT)
- Where
- United States
- Volunteers
- 247 people
- Sponsor
- Qure Healthcare, LLC
Obesity
High Density Lipoprotein Turnover
The objective of the study is to evaluate the effect of Rimonabant 20mg in comparison to placebo, on HDL and VLDL lipoprotein kinetics, over a 12 months period.
- Trial name
- NCT00408148
- Testing
- Rimonabant
- Where
- 4 sites in Australia, Finland and 2 more
- Volunteers
- 64 people
- Sponsor
- Sanofi
Hypercholesterolemia
Investigating Effects of a Novel Nutraceutical on Hypercholesterolaemia in Australian Adults
To evaluate the effects of daily consumption of 3 capsules of Swisse Nutra+ Cholesterol Balance on serum LDL-cholesterol in adults with hypercholesterolaemia compared to placebo over four months.
- Trial name
- CLoNE (NCT04783714)
- Testing
- Swisse Nutra+ Cholesterol Balance
- Where
- Australia
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Swisse Wellness Pty Ltd
Pre-diabetes, Metabolic Syndrome
Replacing Refined Carbohydrates With Healthy Fats on Cardio-metabolic Markers
The primary goal is to to characterize the effects of consuming 1 avocado fruit 7 days / week (5-7 days is acceptable) compared to a no avocado relatively low fat, carbohydrate control treatment over a 12 week period on insulin…
- Trial name
- AV2 (NCT02695433)
- Testing
- Active, Control
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Overweight and Obesity, Dyslipoproteinemia
Effect of Weight Management Programs on Cardiometabolic Risk Profile in Overweight Women
Aim of this prospective randomized study was to evaluate whether a diet with meal replacements can be as effective as a conventional energy-restricted modified diet on weight loss, body composition and cardiometabolic risk…
- Trial name
- FM-01 (NCT03109834)
- Testing
- Meal replacement (MR), Control (C), Verum
- Volunteers
- 105 people
- Sponsor
- Bonn Education Association for Dietetics r.A., Cologne, Germany
Metabolic Cardiovascular Syndrome
Hyperinsulinemic Euglycemic Clamp Protocol
The purpose of the study is to determine the safety and efficacy of TRC150094 in male patients with cardiometabolic risk. Cardiometabolic risk which is the overall risk of cardiovascular disease (CVD) and diabetes resulting from…
- Trial name
- NCT01408667
- Testing
- TRC150094
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Torrent Pharmaceuticals Limited
Psoriasis, Inflammation
A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors
The primary purpose of this proof-of-activity, phase 2 trial is to evaluate the safety and activity of orticumab in subjects with moderate to severe psoriasis and cardiometabolic risk factors.
- Conditions
- Psoriasis, Inflammation, Coronary Artery Disease, Cardiometabolic Syndrome
- Trial name
- NCT04776629
- Testing
- Orticumab
- Where
- 13 sites in United States
- Volunteers
- 77 people
- Sponsor
- Abcentra
Obesity, Microalbuminuria
Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors
Primary objective: To assess the effect on microalbuminuria levels of treatment with rimonabant 20 mg versus a placebo during a 12 month period.
- Conditions
- Obesity, Microalbuminuria, Diabetes Mellitus, Type 2, Dyslipidemia
- Trial name
- RIALTO (NCT00458081)
- Testing
- Rimonabant
- Where
- Spain
- Volunteers
- 174 people
- Sponsor
- Sanofi
Overweight, Obesity
Individual Factors Related to Chronic Low-grade Inflammation and Cardiometabolic Disease Risk
The goal of this observational study is to learn about low-grade inflammation in healthy individuals and individuals with overweight or obesity.
- Conditions
- Overweight, Obesity, Metabolic Syndrome, Healthy
- Trial name
- PINEAPPL (NCT06355544)
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Integrative Phenomics
Acute Myocardial Infarction, Heart Failure
Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.
This study will evaluate the effect of dapagliflozin versus placebo, given once daily in addition to Standard of Care (SoC) therapies for patients with myocardial infarction (MI), for hospitalisation for heart failure (HHF)…
- Trial name
- DAPA-MI (NCT04564742)
- Testing
- Dapagliflozin
- Where
- 103 sites in Sweden, United Kingdom
- Volunteers
- 4,017 people
- Sponsor
- AstraZeneca
Schizophrenia
A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in Patients With Schizophrenia. RESPECT Study.
A 12-Month Observational Prospective Multicentre Cohort Study based on existing and newly collected data of schizophrenia patients followed-up for one year in secondary care settings (psychiatric services).
- Trial name
- RESPECT (NCT04742413)
- Where
- 10 sites in Spain
- Volunteers
- 9 people
- Sponsor
- Angelini Farmacéutica
Cardiometabolic Diseases
Video Vitals and Biomarkers
The investigators are doing this research to study the ability of mobile devices to measure vital signs and biomarkers from video as compared to standard-of-care clinical office tools.
- Trial name
- NCT06136156
- Where
- United States
- Volunteers
- 237 people
- Sponsor
- Maiv Health Inc.
Type II Diabetes Mellitus, Obesity
A Study Evaluating the Effects of a High Viscosity Non-starch Polysaccharide (PolyGlycopleX® - PGX®) on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics
One out of two adults in Canada is currently overweight and therefore at increased risk for a number of medical conditions including diabetes, high blood pressure, heart attacks and stroke.
- Trial name
- NCT01644201
- Testing
- PolyGlycopleX® - PGX®
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- InovoBiologic Inc.
Healthy Volunteers, Cardiometabolic Diseases
A Study to See How Safe a New Medicine (NNC0705-0002) is in Healthy People
This study is testing NNC0705-0002, a new medicine that is being developed for conditions where inflammation may contribute to heart and metabolic health problems.
- Trial name
- NCT07797855
- Testing
- NNC0705-0002
- Where
- Netherlands
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Insulin Resistance
Impact of Starch Digestibility on Glycemic Variability and Control, Cardiometabolic and Inflammatory Profiles, Microbiota and Intestinal Health in Subjects With Insulin Resistance
To study the potential impact of a diet rich in both Slowly Digestible Starch (SDS) and Resistant Starch (RS), we propose a 2-month nutritional intervention study in which we will study the evolution of carbohydrate variability…
- Trial name
- GLYMICARE (NCT07408479)
- Testing
- Balanced diet high in Slowly Digestible Starch and Resistant Starch, Balanced diet low in Slowly Digestible Starch and Resistant Starch
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mondelēz International, Inc.
Obesity
Safety and Tolerance of a Nutritional Intervention Program- In.Form 1.2
The study evaluated and the safety, tolerance and acceptability of a lifestyle modification program with nutritional supplementation in generally healthy overweight subjects with cardiometabolic risk factors.
- Trial name
- NCT03098056
- Testing
- PROG2
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Nature's Sunshine Products, Inc.
Non-Alcoholic Fatty Liver Disease
Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
This clinical trial aims to investigate the effects of TOTUM-448, a mix of 5 plant extracts and choline, consumed at the daily regimen of two times per day, on liver fat content, cardiometabolic risk factors and gut microbiota…
- Trial name
- CARDIO-LIVER (NCT06704321)
- Testing
- TOTUM-448
- Where
- Canada
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Valbiotis